Diabetes pure play embecta, spun out of BD, is a leading force in the global insulin syringe and pen cap arena, but the company has a comprehensive plan to enter higher-growth device markets, including automated insulin delivery (via a patch pump) and, potentially, smart insulin pens. We discuss the company’s growth strategy at length with CEO Dev Kurdikar.
In April 2022, BD spun out its diabetes device business as a new stand-alone pure play named embecta. Although the business initially comprises lower-tech products such as insulin syringes and pen needles, embecta has a comprehensive plan to tap into higher-growth diabetes device and digital technology markets through internal R&D, M&A, and partnering.
We spoke recently with embecta CEO Dev Kurdikar about the new company’s challenges and priorities, its near-term efforts to achieve pipeline expansion, and the scope and objectives of its growth strategies. Kurdikar, who joined BD in February 2021, just a little over a year prior to the spinout, says embecta is committed to investing in R&D and is working diligently on a new insulin patch pump designed specifically for people with type 2 diabetes.